ARMP earnings analysis
What we found in ARMP's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Armata reported Q2 2026 revenue of $2.510 million and diluted EPS of $(0.27), with EPS improving versus both Q1 2026 and Q2 2025. Reported net income of $74.1 million was primarily caused by a $91.0 million non-cash Convertible Loan fair-value gain, while the $10.3 million operating loss indicates that underlying operations remain deeply loss-making. Management maintained its plan to initiate the AP-SA02 Phase 3 superiority study in the second half of 2026, but funding and cash-burn risks remain material; no new material risk-factor changes were reported.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue rebounded sequentially
- Revenue was $2.510 million, up from $789,000 in Q1 2026 and $2.0 million in Q2 2025, according to the reported quarterly results.
- EPS improved materially
- Diluted EPS was $(0.27), improving from $(3.16) in Q1 2026 and $(0.45) in Q2 2025.
- Non-cash gain drove net income
- Reported net income was $74.1 million, primarily reflecting a $91.0 million non-cash fair-value gain on the Convertible Loan.
- Phase 3 timing maintained
- The company maintained its plan to initiate the AP-SA02 Phase 3 superiority study in the second half of 2026.
- Controls remained effective
- Disclosure controls were assessed as effective as of June 30, 2026, and the company reported no changes in internal control that materially affected, or were reasonably likely to materially affect, reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Operating losses remain substantial
- Operating loss was $10.3 million despite reported net income of $74.1 million, highlighting that profitability was driven by the $91.0 million non-cash Convertible Loan fair-value gain rather than operations.
- Funding and liquidity pressure
- The company continues to require funding to support development activities, while operating cash burn remains material; the filing's reported $10.3 million operating loss underscores liquidity risk.
- No material risk-factor updates
- The filing states there were no material changes to the risk factors in the 2025 Form 10-K, so no new risk-factor mitigants were disclosed.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.27
- Gross margin
- 100%
- Segment
- Grant revenue: $2.510 million; no additional segment revenue breakdown disclosed
What they said about what is next.
No numeric financial guidance was provided. Management maintained its expectation to initiate the AP-SA02 Phase 3 superiority study in the second half of 2026.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Armata Pharmaceuticals reported Q4 2026 results showing a revenue increase to $1.085 million, surpassing expectations, but incurred a significant net loss of $115.3 million, reflecting a startling year-over-year…
- 10-K · March 25, 2026
- Armata presents compelling clinical progress (positive Phase 2a results for AP-SA02 and supportive Phase 2 data for AP-PA02) but remains financially stressed. Q4 2025 GAAP EPS was a loss of $(3.43) on revenue of…
- 10-Q · May 14, 2025
- Armata reported Q1 2025 grant and award revenue of $491,000 and GAAP diluted loss per share of $(0.20), improving versus Q1 2024 revenue of $966,000 and diluted loss of $(0.69). Operating loss narrowed to $8.191 million…
- 10-Q · November 13, 2024
- Armata reported Q3 (three months ended September 30, 2024) grant revenue of $2,973,000 (vs. $1,225,000 in Q3 2023) and GAAP diluted loss per share of $(0.15) (vs. $(0.86) in Q3 2023). Operating loss narrowed slightly to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ARMP makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever